Biodexa Historical Financial Ratios

BDRX Stock

1.45 0.04 2.68%

Biodexa Pharmaceticals is presently reporting on over 91 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Ptb Ratio of 0.001, Days Sales Outstanding of 814 or Book Value Per Share of 162 will help investors to properly organize and evaluate Biodexa Pharmaceticals financial condition quickly.

Quick Ratio Current Ratio

Build AI portfolio with Biodexa Stock

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biodexa Pharmaceticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Biodexa Stock please use our How to Invest in Biodexa Pharmaceticals guide.

About Biodexa Financial Ratios Analysis

Biodexa PharmaceticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Biodexa Pharmaceticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Biodexa financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Biodexa Pharmaceticals history.

Biodexa Pharmaceticals Financial Ratios Chart

At this time, Biodexa Pharmaceticals' Enterprise Value Over EBITDA is fairly stable compared to the past year.

Price To Sales Ratio Ptb Ratio Days Sales Outstanding

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Biodexa Pharmaceticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Biodexa Pharmaceticals sales, a figure that is much harder to manipulate than other Biodexa Pharmaceticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Most ratios from Biodexa Pharmaceticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Biodexa Pharmaceticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biodexa Pharmaceticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Biodexa Stock please use our How to Invest in Biodexa Pharmaceticals guide.At this time, Biodexa Pharmaceticals' Enterprise Value Over EBITDA is fairly stable compared to the past year.

	2022	2023	2024	2025 (projected)
PTB Ratio	0.0636	8.89E-4	0.001023	9.72E-4
Price To Sales Ratio	0.29	0.0109	0.0126	0.0119

Ptb Ratio Price To Sales Ratio

Biodexa Pharmaceticals fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Ev To Operating Cash Flow	Pe Ratio	Ev To Free Cash Flow	Intangibles To Total Assets
Price To Sales Ratio		0.82	-0.61	0.3	0.72	-0.48	-0.47	0.82	0.68	-0.48	0.23	-0.63	0.14	-0.1	0.0	0.37	-0.77	0.04	0.02	-0.78	0.14	-0.66	-0.51	-0.6	-0.52	-0.22
Ptb Ratio	0.82		-0.67	-0.14	0.6	-0.06	-0.51	1.0	0.81	-0.05	-0.07	-0.22	-0.12	-0.45	-0.1	-0.08	-0.47	-0.26	0.26	-0.48	-0.12	-0.54	-0.66	-0.41	-0.67	-0.42
Days Sales Outstanding	-0.61	-0.67		-0.17	-0.67	0.28	0.59	-0.67	-0.56	0.27	0.23	0.32	0.0	0.06	0.17	-0.21	0.59	-0.15	-0.25	0.59	0.0	0.54	0.63	0.56	0.63	0.17
Book Value Per Share	0.3	-0.14	-0.17		0.66	-0.97	-0.22	-0.14	-0.38	-0.97	0.69	-0.88	0.62	0.91	0.14	1.0	-0.69	0.84	-0.34	-0.69	0.6	-0.5	0.33	-0.48	0.33	0.27
Free Cash Flow Yield	0.72	0.6	-0.67	0.66		-0.76	-0.6	0.6	0.21	-0.75	0.47	-0.75	0.39	0.41	0.01	0.69	-0.88	0.55	-0.05	-0.89	0.37	-0.79	-0.23	-0.74	-0.24	-0.12
Operating Cash Flow Per Share	-0.48	-0.06	0.28	-0.97	-0.76		0.32	-0.06	0.2	1.0	-0.68	0.97	-0.59	-0.82	-0.12	-0.98	0.74	-0.75	0.28	0.74	-0.58	0.62	-0.24	0.48	-0.24	-0.2
Capex To Depreciation	-0.47	-0.51	0.59	-0.22	-0.6	0.32		-0.51	-0.43	0.31	-0.21	0.36	0.18	-0.09	0.59	-0.24	0.43	-0.14	-0.63	0.44	0.19	0.64	0.37	0.35	0.37	0.06
Pb Ratio	0.82	1.0	-0.67	-0.14	0.6	-0.06	-0.51		0.81	-0.05	-0.07	-0.22	-0.12	-0.45	-0.1	-0.08	-0.47	-0.26	0.26	-0.48	-0.12	-0.54	-0.66	-0.41	-0.67	-0.42
Ev To Sales	0.68	0.81	-0.56	-0.38	0.21	0.2	-0.43	0.81		0.21	-0.34	0.02	-0.41	-0.68	-0.3	-0.32	-0.23	-0.56	0.42	-0.24	-0.4	-0.27	-0.87	-0.22	-0.88	-0.35
Free Cash Flow Per Share	-0.48	-0.05	0.27	-0.97	-0.75	1.0	0.31	-0.05	0.21		-0.68	0.97	-0.59	-0.82	-0.12	-0.99	0.74	-0.75	0.28	0.74	-0.58	0.61	-0.24	0.48	-0.24	-0.21
Inventory Turnover	0.23	-0.07	0.23	0.69	0.47	-0.68	-0.21	-0.07	-0.34	-0.68		-0.63	0.29	0.62	0.12	0.69	-0.47	0.45	-0.37	-0.47	0.27	-0.41	0.39	-0.32	0.39	0.32
Net Income Per Share	-0.63	-0.22	0.32	-0.88	-0.75	0.97	0.36	-0.22	0.02	0.97	-0.63		-0.53	-0.68	-0.11	-0.91	0.72	-0.59	0.22	0.72	-0.52	0.67	-0.16	0.41	-0.16	-0.14
Days Of Inventory On Hand	0.14	-0.12	0.0	0.62	0.39	-0.59	0.18	-0.12	-0.41	-0.59	0.29	-0.53		0.58	0.26	0.61	-0.4	0.7	-0.41	-0.4	1.0	-0.2	0.41	-0.28	0.41	-0.29
Average Inventory	-0.1	-0.45	0.06	0.91	0.41	-0.82	-0.09	-0.45	-0.68	-0.82	0.62	-0.68	0.58		0.13	0.88	-0.36	0.84	-0.32	-0.35	0.56	-0.3	0.59	-0.18	0.59	0.36
Capex To Revenue	0.0	-0.1	0.17	0.14	0.01	-0.12	0.59	-0.1	-0.3	-0.12	0.12	-0.11	0.26	0.13		0.14	-0.06	0.09	-0.84	-0.05	0.26	-0.11	0.22	-0.03	0.21	0.11
Cash Per Share	0.37	-0.08	-0.21	1.0	0.69	-0.98	-0.24	-0.08	-0.32	-0.99	0.69	-0.91	0.61	0.88	0.14		-0.73	0.82	-0.33	-0.72	0.6	-0.53	0.29	-0.51	0.29	0.25
Pocfratio	-0.77	-0.47	0.59	-0.69	-0.88	0.74	0.43	-0.47	-0.23	0.74	-0.47	0.72	-0.4	-0.36	-0.06	-0.73		-0.57	0.18	1.0	-0.39	0.64	0.32	0.92	0.32	0.05
Interest Coverage	0.04	-0.26	-0.15	0.84	0.55	-0.75	-0.14	-0.26	-0.56	-0.75	0.45	-0.59	0.7	0.84	0.09	0.82	-0.57		-0.26	-0.56	0.69	-0.35	0.39	-0.5	0.4	0.0
Capex To Operating Cash Flow	0.02	0.26	-0.25	-0.34	-0.05	0.28	-0.63	0.26	0.42	0.28	-0.37	0.22	-0.41	-0.32	-0.84	-0.33	0.18	-0.26		0.18	-0.41	0.08	-0.31	0.16	-0.31	-0.18
Pfcf Ratio	-0.78	-0.48	0.59	-0.69	-0.89	0.74	0.44	-0.48	-0.24	0.74	-0.47	0.72	-0.4	-0.35	-0.05	-0.72	1.0	-0.56	0.18		-0.38	0.64	0.33	0.92	0.33	0.05
Days Payables Outstanding	0.14	-0.12	0.0	0.6	0.37	-0.58	0.19	-0.12	-0.4	-0.58	0.27	-0.52	1.0	0.56	0.26	0.6	-0.39	0.69	-0.41	-0.38		-0.19	0.42	-0.26	0.42	-0.3
Income Quality	-0.66	-0.54	0.54	-0.5	-0.79	0.62	0.64	-0.54	-0.27	0.61	-0.41	0.67	-0.2	-0.3	-0.11	-0.53	0.64	-0.35	0.08	0.64	-0.19		0.2	0.45	0.21	0.14
Ev To Operating Cash Flow	-0.51	-0.66	0.63	0.33	-0.23	-0.24	0.37	-0.66	-0.87	-0.24	0.39	-0.16	0.41	0.59	0.22	0.29	0.32	0.39	-0.31	0.33	0.42	0.2		0.45	1.0	0.3
Pe Ratio	-0.6	-0.41	0.56	-0.48	-0.74	0.48	0.35	-0.41	-0.22	0.48	-0.32	0.41	-0.28	-0.18	-0.03	-0.51	0.92	-0.5	0.16	0.92	-0.26	0.45	0.45		0.45	0.1
Ev To Free Cash Flow	-0.52	-0.67	0.63	0.33	-0.24	-0.24	0.37	-0.67	-0.88	-0.24	0.39	-0.16	0.41	0.59	0.21	0.29	0.32	0.4	-0.31	0.33	0.42	0.21	1.0	0.45		0.3
Intangibles To Total Assets	-0.22	-0.42	0.17	0.27	-0.12	-0.2	0.06	-0.42	-0.35	-0.21	0.32	-0.14	-0.29	0.36	0.11	0.25	0.05	0.0	-0.18	0.05	-0.3	0.14	0.3	0.1	0.3

Click cells to compare fundamentals

Biodexa Pharmaceticals Account Relationship Matchups

Biodexa Pharmaceticals fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Price To Sales Ratio	2.14	1.35	0.29	0.0109	0.0126	0.0119
Ptb Ratio	0.11	0.0747	0.0636	8.89E-4	0.001023	9.72E-4
Days Sales Outstanding	101.09	20.84	171.8	674.44	775.6	814.38
Book Value Per Share	1.3K	1.0K	255.95	148.11	170.32	161.81
Free Cash Flow Yield	(0.0324)	(0.0203)	(0.0883)	(4.26)	(4.9)	(4.65)
Operating Cash Flow Per Share	(1.7K)	(596.74)	(570.5)	(216.12)	(194.5)	(204.23)
Stock Based Compensation To Revenue	(1.18)	0.15	0.18	0.0735	0.0661	0.0694
Capex To Depreciation	0.17	0.79	0.18	0.93	3.05	3.2
Pb Ratio	0.11	0.0747	0.0636	8.89E-4	0.001023	9.72E-4
Ev To Sales	833.48	524.45	111.97	(10.09)	(9.08)	(8.62)
Free Cash Flow Per Share	(1.8K)	(628.53)	(575.52)	(224.44)	(202.0)	(212.1)
Net Income Per Share	(4.1K)	(542.31)	(619.72)	(224.13)	(201.71)	(211.8)
Days Of Inventory On Hand	(82.77)	7.8E-5	7.1E-5	(63.18)	(72.66)	(69.03)
Sales General And Administrative To Revenue	14.45	5.1	6.5	11.4	13.11	9.3
Research And Ddevelopement To Revenue	47.07	8.05	7.31	10.67	12.28	16.57
Capex To Revenue	0.61	0.55	0.0887	0.69	0.79	1.18
Cash Per Share	1.4K	998.91	229.56	189.05	217.4	206.53
Pocfratio	(0.0788)	(0.13)	(0.0285)	(6.09E-4)	(5.48E-4)	(5.76E-4)
Interest Coverage	(313.85)	(159.05)	(168.53)	(195.46)	(224.78)	(236.02)
Capex To Operating Cash Flow	(0.0225)	(0.0533)	(0.008797)	(0.0385)	(0.0631)	(0.0663)
Pfcf Ratio	(30.83)	(49.37)	(11.32)	(0.23)	(0.21)	(0.22)
Days Payables Outstanding	20.27	38.04	24.21	28.18	32.41	30.79
Income Quality	0.42	1.1	0.92	0.96	2.14	2.25
Ev To Operating Cash Flow	(30.74)	(50.45)	(11.1)	0.56	0.0768	0.0807
Pe Ratio	(0.033)	(0.14)	(0.0263)	(5.88E-4)	(5.29E-4)	(5.55E-4)
Ev To Free Cash Flow	(30.06)	(47.9)	(11.01)	0.54	0.0723	0.0759
Net Debt To E B I T D A	0.33	1.64	0.3	0.77	0.88	1.05
Current Ratio	3.1	6.39	2.47	1.26	1.75	3.36
Tangible Book Value Per Share	1.3K	1.0K	255.46	54.99	63.24	60.08
Shareholders Equity Per Share	1.3K	1.0K	255.95	148.11	170.32	161.81
Debt To Equity	0.0387	0.0733	0.2	0.0992	0.0874	0.083
Capex Per Share	15.6K	12.7K	2.0K	3.3K	3.8K	3.6K
Graham Net Net	715.27	756.97	58.26	8.96	10.3	9.79
Revenue Per Share	64.05	57.41	56.58	12.06	13.87	13.18
Interest Debt Per Share	54.9	80.45	54.8	15.99	18.39	17.47
Debt To Assets	0.0265	0.0593	0.11	0.044	0.0492	0.0467
Enterprise Value Over E B I T D A	(12.87)	(53.57)	(10.58)	0.54	0.62	0.65

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

AMT	American Tower Corp
HLTOY	Hellenic Telecommunications Org
NFLX	Netflix

Additional Tools for Biodexa Stock Analysis

When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Ptb Ratio
Days Sales Outstanding	Book Value Per Share
Free Cash Flow Yield	Invested Capital
Operating Cash Flow Per Share	Average Payables
Stock Based Compensation To Revenue	Capex To Depreciation
Pb Ratio	Ev To Sales
Free Cash Flow Per Share	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Sales General And Administrative To Revenue	Average Inventory
Research And Ddevelopement To Revenue	Capex To Revenue
Cash Per Share	Pocfratio
Interest Coverage	Payout Ratio
Capex To Operating Cash Flow	Pfcf Ratio
Days Payables Outstanding	Net Current Asset Value
Income Quality	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Ev To Free Cash Flow	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Dividend Yield	Roic
Payables Turnover	Roe
Return On Tangible Assets	Earnings Yield
Receivables Turnover	Short Term Coverage Ratios
Price Earnings Ratio	Operating Cycle
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Capital Expenditure Coverage Ratio	Price Cash Flow Ratio
Enterprise Value Multiple	Debt Ratio
Cash Flow To Debt Ratio	Price Sales Ratio
Net Profit Margin	Gross Profit Margin
Price Fair Value	Return On Capital Employed
Fixed Asset Turnover	Return On Assets
Asset Turnover	Return On Equity

Biodexa Historical Financial Ratios

About Biodexa Financial Ratios Analysis

Biodexa Pharmaceticals Financial Ratios Chart

Price To Sales Ratio

Ptb Ratio

Biodexa Pharmaceticals fundamentals Correlations

Biodexa Pharmaceticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Biodexa Pharmaceticals fundamentals Accounts

Also Currently Popular

Additional Tools for Biodexa Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Cash Per Share	+ 1.0	Book Value Per Share
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Days Payables Outstanding	+ 1.0	Days Of Inventory On Hand
Pfcf Ratio	+ 1.0	Pocfratio
Ev To Free Cash Flow	+ 1.0	Ev To Operating Cash Flow

Cash Per Share	- 0.99	Free Cash Flow Per Share
Cash Per Share	- 0.98	Operating Cash Flow Per Share
Free Cash Flow Per Share	- 0.97	Book Value Per Share
Operating Cash Flow Per Share	- 0.97	Book Value Per Share
Cash Per Share	- 0.91	Net Income Per Share
Pfcf Ratio	- 0.89	Free Cash Flow Yield